Synthetic mescaline. Normally biosynthesized from peyote and some other cacti, mescaline was the first psychedelic compound to be extracted and isolated.[1]
Synthetic mescaline. Normally biosynthesized from peyote and some other cacti, mescaline was the first psychedelic compound to be extracted and isolated.[1]

Psychedelics are a subclass of hallucinogenic drugs whose primary effect is to trigger non-ordinary mental states (known as psychedelic experiences or psychedelic "trips") and/or an apparent expansion of consciousness.[2][3][4] Sometimes, they are called classic hallucinogens, serotonergic hallucinogens, or serotonergic psychedelics, and the term psychedelic is sometimes used more broadly to include various types of hallucinogens or those which are atypical or adjacent to psychedelia such as MDMA or cannabis; this article uses the narrower definition of psychedelics. True psychedelics cause specific psychological, visual, and auditory changes, and oftentimes a substantially altered state of consciousness.[5][6][3][7] Psychedelic states are often compared to meditative, psychodynamic or transcendental types of alterations of mind.[4][5][8] The "classical" psychedelics, the psychedelics with the largest scientific and cultural influence, are mescaline, LSD, psilocybin, and DMT.[5][9][10][4] LSD in particular has long been considered the paradigmatic psychedelic compound, to which all other psychedelics are often or usually compared.

Most psychedelic drugs fall into one of the three families of chemical compounds: tryptamines, phenethylamines, or lysergamides (LSD is considered both a tryptamine and lysergamide). They act via serotonin 2A receptor agonism.[2][11][12][13] When compounds bind to serotonin 5-HT2A receptors,[14] they modulate the activity of key circuits in the brain involved with sensory perception and cognition, however, the exact nature of how psychedelics induce changes in perception and cognition via the 5-HT2A receptor is still unknown, although reduction in default mode network activity and increased functional connectivity between regions in the brain as a result may be one of the most relevant pharmacological mechanisms underpinning the psychedelic experience,[15][16] particularly ego death.[17] The psychedelic experience is often compared to non-ordinary forms of consciousness such as those experienced in meditation,[18][3] mystical experiences,[8][7] and near-death experiences,[7] which also appear to be partially underpinned by altered default mode network activity.[19][20] The phenomenon of ego death is often described as a key feature of the psychedelic experience.[18][3][7]

Many psychedelic drugs are illegal worldwide under the UN conventions, with occasional exceptions for religious use or research contexts. Despite these controls, recreational use of psychedelics is common.[21][22] Legal barriers have made the scientific study of psychedelics more difficult. Research has been conducted, however, and studies show that psychedelics are physiologically safe and rarely lead to addiction.[23][24] Studies conducted using psilocybin in a psychotherapeutic setting reveal that psychedelic drugs may assist with treating depression, alcohol addiction, and nicotine addiction.[13][25] Although further research is needed, existing results suggest that psychedelics could be effective treatments for certain forms of psychopathology.[26][27][28][22] A 2022 survey found that 28% of Americans had used a psychedelic at some point in their life.[29]

Etymology and nomenclature

5-HT2A receptor
5-HT2A receptor

The term psychedelic was coined by the psychiatrist Humphrey Osmond during written correspondence with author Aldous Huxley and presented to the New York Academy of Sciences by Osmond in 1957.[30] It is irregularly[31] derived from the Greek words ψυχή psychḗ 'soul, mind' and δηλείν dēleín 'to manifest', with the intended meaning "mind manifesting," the implication being that psychedelics can reveal unused potentials of the human mind.[32] The term was loathed by American ethnobotanist Richard Schultes but championed by American psychologist Timothy Leary.[33]

Aldous Huxley had suggested his own coinage phanerothyme (Greek phaneroein- "visible" and Greek thymos "soul", thus "visible soul") to Osmond in 1956.[34] Recently, the term entheogenic has come into use to denote the use of psychedelic drugs, as well as various other types of psychoactive substances, in a religious, spiritual, and mystical context.[35]

In 2004, David E. Nichols wrote the following about the nomenclature used for psychedelic drugs:[35]

Many different names have been proposed over the years for this drug class. The famous German toxicologist Louis Lewin used the name phantastica earlier in this century, and as we shall see later, such a descriptor is not so farfetched. The most popular names—hallucinogen, psychotomimetic, and psychedelic ("mind manifesting")—have often been used interchangeably. Hallucinogen is now, however, the most common designation in the scientific literature, although it is an inaccurate descriptor of the actual effects of these drugs. In the lay press, the term psychedelic is still the most popular and has held sway for nearly four decades. Most recently, there has been a movement in nonscientific circles to recognize the ability of these substances to provoke mystical experiences and evoke feelings of spiritual significance. Thus, the term entheogen, derived from the Greek word entheos, which means "god within", was introduced by Ruck et al. and has seen increasing use. This term suggests that these substances reveal or allow a connection to the "divine within". Although it seems unlikely that this name will ever be accepted in formal scientific circles, its use has dramatically increased in the popular media and on internet sites. Indeed, in much of the counterculture that uses these substances, entheogen has replaced psychedelic as the name of choice and we may expect to see this trend continue.

Robin Carhart-Harris and Guy Goodwin write that the term psychedelic is preferable to hallucinogen for describing classical psychedelics because of the term hallucinogen's "arguably misleading emphasis on these compounds' hallucinogenic properties."[36]

While the term psychedelic is most commonly used to refer only to serotonergic hallucinogens,[13][12][37][38] it is sometimes used for a much broader range of drugs, including empathogen–entactogens, dissociatives, and atypical hallucinogens/psychoactives such as Amanita muscaria, Cannabis sativa, Nymphaea nouchali and Salvia divinorum.[27][39] Thus, the term serotonergic psychedelic is sometimes used for the narrower class.[40][41] It is important to check the definition of a given source.[35] This article uses the more common, narrower definition of psychedelic.


Doses of lysergic acid diethylamide (LSD)
Free base N,N-DMT extracted from Mimosa hostilis root bark (left); vape cartridge made with freebase N,N-DMT extract (right)
Free base N,N-DMT extracted from Mimosa hostilis root bark (left); vape cartridge made with freebase N,N-DMT extract (right)

Main article: List of psychedelic drugs



Preparation of Ayahuasca, Province of Pastaza, Ecuador.
Preparation of Ayahuasca, Province of Pastaza, Ecuador.

A number of frequently mentioned or traditional psychedelics such as Ayahuasca (which contains DMT), San Pedro, Peyote, and Peruvian torch (which all contain mescaline), Psilocybe mushrooms (which contain psilocin/psilocybin) and Tabernanthe iboga (which contains the unique psychedelic ibogaine) all have a long and extensive history of spiritual, shamanic and traditional usage by indigenous peoples in various world regions, particularly in Latin America, but also Gabon, Africa in the case of iboga.[52] Different countries and/or regions have come to be associated with traditional or spiritual use of particular psychedelics, such as the ancient and entheogenic use of psilocybe mushrooms by the native Mazatec people of Oaxaca, Mexico[53] or the use of the ayahuasca brew in the Amazon basin, particularly in Peru for spiritual and physical healing as well as for religious festivals.[54] Peyote has also been used for several thousand years in the Rio Grande Valley in North America by native tribes as an entheogen.[citation needed] In the Andean region of South America, the San Pedro cactus (Echinopsis pachanoi) has a long history of use, possibly as a traditional medicine. Archaeological studies have found evidence of use going back two thousand years, to Moche culture,[55] Nazca culture,[56] and Chavín culture. Although authorities of the Roman Catholic church attempted to suppress its use after the Spanish conquest,[57] this failed, as shown by the Christian element in the common name "San Pedro cactus" – Saint Peter cactus. The name is attributed[by whom?] to the belief that just as St Peter holds the keys to heaven, the effects of the cactus allow users "to reach heaven while still on earth."[58] In 2022, the Peruvian Ministry of Culture declared the traditional use of San Pedro cactus in northern Peru as cultural heritage.[59]

Although people of western culture have tended to use psychedelics for either psychotherapeutic or recreational reasons, most indigenous cultures, particularly in South America have seemingly tended to use psychedelics for more supernatural reasons such as divination. This can often be related to "healing" or health as well but typically in the context of finding out what is wrong with the individual; such as using psychedelic states to "identify" a disease and/or its cause, locate lost objects, and identify a victim or even perpetrator of sorcery.[60] In some cultures and regions, even psychedelics themselves, such as ayahuasca and the psychedelic lichen of eastern Ecuador (Dictyonema huaorani) that supposedly contains both 5-MeO-DMT and psilocybin, have also been used by witches and sorcerers to conduct their malicious magic, similarly to nightshade deliriants like brugmansia and latua.[60][citation needed]

Psychedelic therapy

Main article: Psychedelic therapy

Psychedelic therapy (or psychedelic-assisted therapy) is the proposed use of psychedelic drugs to treat mental disorders.[27][38] As of 2021, psychedelic drugs are controlled substances in most countries and psychedelic therapy is not legally available outside clinical trials, with some exceptions.[38][61]

The procedure for psychedelic therapy differs from that of therapies using conventional psychiatric medications. While conventional medications are usually taken without supervision at least once daily, in contemporary psychedelic therapy the drug is administered in a single session (or sometimes up to three sessions) in a therapeutic context.[62] The therapeutic team prepares the patient for the experience beforehand and helps them integrate insights from the drug experience afterwards.[63][64] After ingesting the drug, the patient normally wears eyeshades and listens to music to facilitate focus on the psychedelic experience, with the therapeutic team interrupting only to provide reassurance if adverse effects such as anxiety or disorientation arise.[63][64]

As of 2022, the body of high-quality evidence on psychedelic therapy remains relatively small and more, larger studies are needed to reliably show the effectiveness and safety of psychedelic therapy's various forms and applications.[26][27] On the basis of favorable early results, ongoing research is examining proposed psychedelic therapies for conditions including major depressive disorder,[26][65] and anxiety and depression linked to terminal illness.[26][66] The United States Food and Drug Administration has granted "breakthrough therapy" status, which expedites the assessment of promising drug therapies for potential approval,[note 1] to psilocybin therapy for treatment-resistant depression and major depressive disorder.[38]


Further information: Recreational drug use § Hallucinogens

Recreational use of psychedelics is common.[21][22] A survey published in 2013 found that 13.4% of American adults had used a psychedelic.[68]


Main article: Psychedelic microdosing

Psychedelic microdosing is the practice of using sub-threshold doses (microdoses) of psychedelics in an attempt to improve creativity, boost physical energy level, emotional balance, increase performance on problems-solving tasks and to treat anxiety, depression and addiction.[69][70] The practice of microdosing has become more widespread in the 21st century with more people claiming long-term benefits from the practice.[71][72]

A 2022 study recognized signatures of psilocybin microdosing in natural language and concluded that low amount of psychedelics have potential for application, and ecological observation of microdosing schedules.[73][74]


While the method of action of psychedelics is not fully understood, they are known to show affinities for various 5-HT (serotonin) receptors in different ways and levels, and may be classified by their activity at different 5-HT sub-types, particularly 5-HT1A, 5-HT2A, and 5-HT2C.[35] It is almost unanimously agreed that psychedelics produce their effect by acting as strong partial agonists at the 5-HT2A receptors.[2][75][12][13] How this produces the psychedelic experience is unclear, but it is likely that it acts by increasing excitation in the cortex, possibly by specifically facilitating input from the thalamus, the major relay for sensory information input to the cortex.[35] Additionally, researchers discovered that many psychedelics are potent psychoplastogens, compounds capable of promoting rapid and sustained neural plasticity.[76][77]



Tryptamine, along with other trace amines, is found in the central nervous system of mammals. It is hypothesized to play a role as a neuromodulator on classical monoamine neurotransmitters, such as dopamine, serotonin, and norepinephrine (epinephrine). Tryptamine acts as a non-selective serotonin receptor agonist to activate serotonin receptors, and a serotonin–norepinephrine–dopamine releasing agent (SNDRA) to release more monoamine neurotransmitter, with a preference for evoking serotonin and dopamine release over norepinephrine (epinephrine) release.[78][79][80] Psychedelic tryptamines found in nature include psilocin, DMT, 5-MeO-DMT, and tryptamines that have been synthesized in the laboratory include 4-HO-MET,[81] 4-HO-MiPT,[51] and 5-MeO-DALT.[82]



Phenethylamine is also a trace amine but to a lesser extent acts as a neurotransmitter in the human central nervous system (CNS). Phenethylamine instead regulates monoamine neurotransmission by binding to trace amine-associated receptor 1 (TAAR1), which plays a significant role in regulating neurotransmission in dopamine, norepinephrine, and serotonin neurons in the CNS and inhibiting vesicular monoamine transporter 2 (VMAT2) in monoamine neurons.[83][84] When VMAT2 is inhibited monoamine neurotransmitters such as dopamine cannot be released into the synapse via typical release mechanisms.[85] Mescaline is a naturally occurring psychedelic protoalkaloid of the substituted phenethylamine class.


Lysergic acid diethylamide (LSD)
Lysergic acid diethylamide (LSD)

Amides of lysergic acid are collectively known as lysergamides, and include a number of compounds with potent agonist and/or antagonist activity at various serotonin and dopamine receptors. Lysergamides contain both Tryptamine and Phenethylamine structure although it is class as a complex Tryptamine. LSD (Lysergic Acid Diethylamide) is one of many lysergamides. A wide range of lysergamides have emerged in recent years, inspired by existing scientific literature. Others, have appeared from chemical research.[86] 1P-LSD is a derivative and functional analogue of LSD and a homologue of ALD-52. It modifies the LSD molecule by adding a propionyl group to the nitrogen molecule of LSD's indole.[87]

Psychedelic experiences

Main article: Psychedelic experience

Although several attempts have been made, starting in the 19th and 20th centuries, to define common phenomenological structures of the effects produced by classic psychedelics, a universally accepted taxonomy does not yet exist.[88][89] At lower doses, features of psychedelic experiences include sensory alterations, such as the warping of surfaces, shape suggestibility, pareidolia and color variations. Users often report intense colors that they have not previously experienced, and repetitive geometric shapes or form constants are common as well. Higher doses often cause intense and fundamental alterations of sensory (notably visual) perception, such as synesthesia or the experience of additional spatial or temporal dimensions.[90] Tryptamines are well documented to cause classic psychedelic states, such as increased empathy, visual distortions (drifting, morphing, breathing, melting of various surfaces and objects), auditory hallucinations, ego dissolution or ego death with high enough dose, mystical, transpersonal and spiritual experiences, autonomous "entity" encounters, time distortion, closed eye hallucinations and complete detachment from reality with a high enough dose.[91] Luis Luna describes psychedelic experiences as having a distinctly gnosis-like quality, and says that they offer "learning experiences that elevate consciousness and can make a profound contribution to personal development."[92] Czech psychiatrist Stanislav Grof studied the effects of psychedelics like LSD early in his career and said of the experience, that it commonly includes "complex revelatory insights into the nature of existence… typically accompanied by a sense of certainty that this knowledge is ultimately more relevant and 'real' than the perceptions and beliefs we share in everyday life."[citation needed] Traditionally, the standard model for the subjective phenomenological effects of psychedelics has typically been based on LSD, with anything that is considered "psychedelic" evidently being compared to it and its specific effects.[93]

During a speech on his 100th birthday, the inventor of LSD, Albert Hofmann said of the drug: "It gave me an inner joy, an open mindedness, a gratefulness, open eyes and an internal sensitivity for the miracles of creation... I think that in human evolution it has never been as necessary to have this substance LSD. It is just a tool to turn us into what we are supposed to be."[94] With certain psychedelics and experiences, a user may also experience an "afterglow" of improved mood or perceived mental state for days or even weeks after ingestion in some cases.[95] In 1898, the English writer and intellectual Havelock Ellis reported a heightened perceptual sensitivity to "the more delicate phenomena of light and shade and color" for a prolonged period of time after his exposure to mescaline.[96] Good trips are reportedly deeply pleasurable, and typically involve intense joy or euphoria, a greater appreciation for life, reduced anxiety, a sense of spiritual enlightenment, and a sense of belonging or interconnectedness with the universe.[97][98] Negative experiences, colloquially known as "bad trips," evoke an array of dark emotions, such as irrational fear, anxiety, panic, paranoia, dread, distrustfulness, hopelessness, and even suicidal ideation.[99] While it is impossible to predict when a bad trip will occur, one's mood, surroundings, sleep, hydration, social setting, and other factors can be controlled (colloquially referred to as "set and setting") to minimize the risk of a bad trip.[100][101] The concept of “set and setting" also generally appears to be more applicable to psychedelics than to other types of hallucinogens such as deliriants, hypnotics and dissociative anesthetics.[102]

Classic psychedelics are considered to be those found in nature like psilocybin, DMT, mescaline, and LSD which is derived from naturally occurring ergotamine, and non-classic psychedelics are considered to be newer analogs and derivatives of pharmacophore lysergamides, tryptamine, and phenethylamine structures like 2C-B. Many of these psychedelics cause remarkably similar effects, despite their different chemical structure. However, many users report that the three major families have subjectively different qualities in the "feel" of the experience, which are difficult to describe. Some compounds, such as 2C-B, have extremely tight "dose curves", meaning the difference in dose between a non-event and an overwhelming disconnection from reality can be very slight. There can also be very substantial differences between the drugs; for instance, 5-MeO-DMT rarely produces the visual effects typical of other psychedelics.[13]

Potential adverse effects

See also: Bad trip and Trip sitter

Despite the contrary perception of much of the public, psychedelic drugs are not addictive and are physiologically safe.[23][24][13] As of 2016, there have been no known deaths due to overdose of LSD, psilocybin, or mescaline.[13]

Risks do exist during an unsupervised psychedelic experience, however; Ira Byock wrote in 2018 in the Journal of Palliative Medicine that psilocybin is safe when administered to a properly screened patient and supervised by a qualified professional with appropriate set and setting. However, he called for an "abundance of caution" because in the absence of these conditions a range of negative reactions is possible, including "fear, a prolonged sense of dread, or full panic." He notes that driving or even walking in public can be dangerous during a psychedelic experience because of impaired hand-eye coordination and fine motor control.[103] In some cases, individuals taking psychedelics have performed dangerous or fatal acts because they believed they possessed superhuman powers.[13]

Psilocybin-induced states of mind share features with states experienced in psychosis, and while a causal relationship between psilocybin and the onset of psychosis has not been established as of 2011, researchers have called for investigation of the relationship.[104] Many of the persistent negative perceptions of psychological risks are unsupported by the currently available scientific evidence, with the majority of reported adverse effects not being observed in a regulated and/or medical context.[105] A population study on associations between psychedelic use and mental illness published in 2013 found no evidence that psychedelic use was associated with increased prevalence of any mental illness.[106]

Using psychedelics poses certain risks of re-experiencing of the drug's effects, including flashbacks and hallucinogen persisting perception disorder (HPPD).[104] These non-psychotic effects are poorly studied, but the permanent symptoms (also called "endless trip") are considered to be rare.[107]

Serotonin syndrome can be caused by combining psychedelics with other serotonergic drugs, including certain antidepressants, opioids, CNS stimulants (e.g. MDMA), 5-HT1 agonists (e.g. triptans), herbs and others.[108][109][110][111]

Potential therapeutic effects

Further information: Psychedelic therapy

Psilocybin session at Johns Hopkins
Psilocybin session at Johns Hopkins

Psychedelic substances which may have therapeutic uses include psilocybin, LSD, and mescaline.[28] During the 1950s and 1960s, lack of informed consent in some scientific trials on psychedelics led to significant, long-lasting harm to some participants.[28] Since then, research regarding the effectiveness of psychedelic therapy has been conducted under strict ethical guidelines, with fully informed consent and a pre-screening to avoid people with psychosis taking part.[28] Although the history behind these substances has hindered research into their potential medicinal value, scientists are now able to conduct studies and renew research that was halted in the 1970s. Some research has shown that these substances have helped people with such mental disorders as obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), alcoholism, depression, and cluster headaches.[22]

It has long been known that psychedelics promote neurite growth and neuroplasticity and are potent psychoplastogens.[112][113][114] There is evidence that psychedelics induce molecular and cellular adaptations related to neuroplasticity and that these could potentially underlie therapeutic benefits.[115][116] Psychedelics have also been shown to have potent anti-inflammatory activity and therapeutic effects in animal models of inflammatory diseases including asthma,[117] and cardiovascular disease and diabetes.[118]

Surrounding culture

Psychedelic rock band Jefferson Airplane in 1967

Main article: Psychedelia

Psychedelic culture includes manifestations such as psychedelic music,[119] psychedelic art,[120] psychedelic literature,[121] psychedelic film,[122] and psychedelic festivals.[123] Examples of psychedelic music would be rock bands like the Grateful Dead, Jefferson Airplane and The Beatles. Many psychedelic bands and elements of the psychedelic subculture originated in San Francisco during the mid to late 1960s.[124]

Legal status

See also: Legal status of psilocybin mushrooms, Psilocybin decriminalization in the United States, and Legal status of ayahuasca by country

Many psychedelics are classified under Schedule I of the United Nations Convention on Psychotropic Substances of 1971 as drugs with the greatest potential to cause harm and no acceptable medical uses.[125] In addition, many countries have analogue laws; for example, in the United States, the Federal Analogue Act of 1986 automatically forbids any drugs sharing similar chemical structures or chemical formulas to illicit or prohibited substances if sold for human consumption.[126]

U.S. states such as Oregon and Colorado have also instituted decriminalization and legalization measures of psychedelics[127] and states like New Hampshire and others are attempting to do the same.[128] J.D. Tuccille argues that increasing rates of use of psychedelics in defiance of the law are likely to result in more widespread legalization and decriminalization of the substances in the United States (as has happened with alcohol and cannabis).[129]

See also



  1. ^ The Food and Drug Administration describes the designation of breakthrough therapy as "a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s)."[67]


  1. ^ "Peyote San Pedro Cactus – Shamanic Sacraments". D.M.Taylor.
  2. ^ a b c Aghajanian, G (August 1999). "Serotonin and Hallucinogens". Neuropsychopharmacology. 21 (2): 16S–23S. doi:10.1016/S0893-133X(98)00135-3. PMID 10432484.
  3. ^ a b c d Millière, Raphaël; Carhart-Harris, Robin L.; Roseman, Leor; Trautwein, Fynn-Mathis; Berkovich-Ohana, Aviva (2018). "Psychedelics, Meditation, and Self-Consciousness". Frontiers in Psychology. 9: 1475. doi:10.3389/fpsyg.2018.01475. PMC 6137697. PMID 30245648.
  4. ^ a b c Pollan, Michael (2018). How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence
  5. ^ a b c Leary, Timothy; Metzner, Ralph (1964). The Psychedelic Experience: A Manual Based on The Tibetan Book of the Dead
  6. ^ McKenna, Terence (1989). True Hallucinations: Being an Account of the Author's Extraordinary Adventures in the Devil's Paradise
  7. ^ a b c d Timmermann, Christopher; Roseman, Leor; Williams, Luke; Erritzoe, David; Martial, Charlotte; Cassol, Héléna; Laureys, Steven; Nutt, David; Carhart-Harris, Robin (2018). "DMT Models the Near-Death Experience". Frontiers in Psychology. 9: 1424. doi:10.3389/fpsyg.2018.01424. PMC 6107838. PMID 30174629.
  8. ^ a b R. R. Griffiths; W. A. Richards; U. McCann; R. Jesse (7 July 2006). "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance". Psychopharmacology. 187 (3): 268–283. doi:10.1007/s00213-006-0457-5. PMID 16826400. S2CID 7845214.
  9. ^ McKenna, Terence (1992). Food of the Gods: The Search for the Original Tree of Knowledge A Radical History of Plants, Drugs, and Human Evolution
  10. ^ W. Davis (1996), One River: Explorations and Discoveries in the Amazon Rain Forest. New York, Simon and Schuster, Inc. p. 120.
  11. ^ "Crystal Structure of LSD and 5-HT2AR Part 2: Binding Details and Future Psychedelic Research Paths". Psychedelic Science Review. 2020-10-05. Retrieved 2021-02-12.
  12. ^ a b c Nichols, David E. (2018). "Chemistry and Structure–Activity Relationships of Psychedelics". In Halberstadt, Adam L.; Vollenweider, Franz X.; Nichols, David E. (eds.). Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Vol. 36. Berlin: Springer. pp. 1–43. doi:10.1007/7854_2017_475. ISBN 978-3-662-55880-5. PMID 28401524.
  13. ^ a b c d e f g h Nichols, David E. (2016). "Psychedelics". Pharmacological Reviews. 68 (2): 264–355. doi:10.1124/pr.115.011478. ISSN 0031-6997. PMC 4813425. PMID 26841800.
  14. ^ Siegel, George J. (11 November 2005). Basic neurochemistry : molecular, cellular and medical aspects (7th ed.). Amsterdam. ISBN 978-0-08-047207-2. OCLC 123438340.
  15. ^ Smigielski, Lukasz; Scheidegger, Milan; Kometer, Michael; Vollenweider, Franz X. (August 2019). "Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects". NeuroImage. 196: 207–215. doi:10.1016/j.neuroimage.2019.04.009. PMID 30965131. S2CID 102487343.
  16. ^ Palhano-Fontes, Fernanda; Andrade, Katia C.; Tofoli, Luis F.; Santos, Antonio C.; Crippa, Jose Alexandre S.; Hallak, Jaime E. C.; Ribeiro, Sidarta; Araujo, Draulio B. de (2015-02-18). "The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network". PLOS ONE. 10 (2): e0118143. Bibcode:2015PLoSO..1018143P. doi:10.1371/journal.pone.0118143. ISSN 1932-6203. PMC 4334486. PMID 25693169.
  17. ^ Tagliazucchi, Enzo; Roseman, Leor; Kaelen, Mendel; Orban, Csaba; Muthukumaraswamy, Suresh; Murphy, Kevin; Laufs, Helmut; Leech, Robert; McGonigle, John; Crossley, Nicolas; Bullmore, Edward (2016). "Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution". Current Biology. 26 (8): 1043–1050. doi:10.1016/j.cub.2016.02.010. PMID 27085214. S2CID 3865696.
  18. ^ a b Letheby, Chris; Gerrans, Philip (2017). "Self unbound: ego dissolution in psychedelic experience". Neuroscience of Consciousness. 3 (1): nix016. doi:10.1093/nc/nix016. PMC 6007152. PMID 30042848. The connection with findings about PCC deactivation in 'effortless awareness' meditation is obvious, and bolstered by the finding that acute ayahuasca intoxication increases mindfulness-related capacities.
  19. ^ Brewer, Judson A.; Worhunsky, Patrick D.; Gray, Jeremy R.; Tang, Yi-Yuan; Weber, Jochen; Kober, Hedy (2011-12-13). "Meditation experience is associated with differences in default mode network activity and connectivity". Proceedings of the National Academy of Sciences. 108 (50): 20254–20259. Bibcode:2011PNAS..10820254B. doi:10.1073/pnas.1112029108. PMC 3250176. PMID 22114193.
  20. ^ Rim, James I.; Ojeda, Jesse Caleb; Svob, Connie; Kayser, Jürgen; Drews, Elisa; Kim, Youkyung; Tenke, Craig E.; Skipper, Jamie; Weissman, Myrna M. (2019). "Current Understanding of Religion, Spirituality, and Their Neurobiological Correlates". Harvard Review of Psychiatry. 27 (5): 303–316. doi:10.1097/HRP.0000000000000232. ISSN 1465-7309. PMC 7195862. PMID 31490186.
  21. ^ a b Krebs, Teri S; Johansen, Pål-Ørjan (28 March 2013). "Over 30 million psychedelic users in the United States". F1000Research. 2: 98. doi:10.12688/f1000research.2-98.v1. PMC 3917651. PMID 24627778.
  22. ^ a b c d Garcia-Romeu, Albert; Kersgaard, Brennan; Addy, Peter H. (August 2016). "Clinical applications of hallucinogens: A review". Experimental and Clinical Psychopharmacology. 24 (4): 229–268. doi:10.1037/pha0000084. PMC 5001686. PMID 27454674.
  23. ^ a b Le Dain, Gerald (1971). The Non-medical Use of Drugs: Interim Report of the Canadian Government's Commission of Inquiry. p. 106. Physical dependence does not develop to LSD
  24. ^ a b Lüscher, Christian; Ungless, Mark A. (14 November 2006). "The Mechanistic Classification of Addictive Drugs". PLOS Medicine. 3 (11): e437. doi:10.1371/journal.pmed.0030437. PMC 1635740. PMID 17105338.
  25. ^ Rich Haridy (24 October 2018). "Psychedelic psilocybin therapy for depression granted Breakthrough Therapy status by FDA". Retrieved 2019-09-27.
  26. ^ a b c d Bender, David; Hellerstein, David J. (2022). "Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research". Psychopharmacology. 239 (6): 1907–1932. doi:10.1007/s00213-021-06049-6. PMID 35022823. S2CID 245906937.
  27. ^ a b c d Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. (May 2020). "Psychedelics and Psychedelic-Assisted Psychotherapy". The American Journal of Psychiatry. 177 (5): 391–410. doi:10.1176/appi.ajp.2019.19010035. PMID 32098487. S2CID 211524704.
  28. ^ a b c d Tupper, Kenneth W.; Wood, Evan; Yensen, Richard; Johnson, Matthew W. (2015-10-06). "Psychedelic medicine: a re-emerging therapeutic paradigm". CMAJ: Canadian Medical Association Journal. 187 (14): 1054–1059. doi:10.1503/cmaj.141124. ISSN 0820-3946. PMC 4592297. PMID 26350908.
  29. ^ "One in four Americans say they've tried at least one psychedelic drug". July 28, 2022.
  30. ^ Tanne, Janice Hopkins (2004). "Humphrey Osmond". BMJ. 328 (7441): 713. doi:10.1136/bmj.328.7441.713. PMC 381240.
  31. ^ Oxford English Dictionary, 3rd edition, September 2007, s.v., Etymology
  32. ^ A. Weil, W. Rosen. (1993), From Chocolate To Morphine: Everything You Need To Know About Mind-Altering Drugs. New York, Houghton Mifflin Company. p. 93
  33. ^ W. Davis (1996), "One River: Explorations and Discoveries in the Amazon Rain Forest". New York, Simon and Schuster, Inc. p. 120.
  34. ^
  35. ^ a b c d e Nichols, David E. (2004). "Hallucinogens". Pharmacology & Therapeutics. 101 (2): 131–81. doi:10.1016/j.pharmthera.2003.11.002. PMID 14761703.
  36. ^ Carhart-Harris, Robin; Guy, Goodwin (2017). "The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future". Neuropsychopharmacology. 42 (11): 2105–2113. doi:10.1038/npp.2017.84. PMC 5603818. PMID 28443617.
  37. ^ DiVito, Alec J.; Leger, Robert F. (2020). "Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review". Molecular Biology Reports. 47 (12): 9791–9799. doi:10.1007/s11033-020-06009-x. PMID 33231817. S2CID 227157734.
  38. ^ a b c d Marks M, Cohen IG (October 2021). "Psychedelic therapy: a roadmap for wider acceptance and utilization". Nature Medicine. 27 (10): 1669–1671. doi:10.1038/s41591-021-01530-3. PMID 34608331. S2CID 238355863.
  39. ^ Siegel, Ashley N.; Meshkat, Shakila; Benitah, Katie; Lipstiz, Orly; Gill, Hartej; Lui, Leanna M. W.; Teopiz, Kayla M.; McIntyre, Roger S.; Rosenblat, Joshua D. (2021). "Registered clinical studies investigating psychedelic drugs for psychiatric disorders". Journal of Psychiatric Research. 139: 71–81. doi:10.1016/j.jpsychires.2021.05.019. PMID 34048997. S2CID 235242044.
  40. ^ Andersen, Kristoffer A. A.; Carhart-Harris, Robin; Nutt, David J.; Erritzoe, David (2020). "Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies". Acta Psychiatrica Scandinavica. 143 (2): 101–118. doi:10.1111/acps.13249. PMID 33125716. S2CID 226217912.
  41. ^ Malcolm, Benjamin; Thomas, Kelan (2022). "Serotonin toxicity of serotonergic psychedelics". Psychopharmacology. 239 (6): 1881–1891. doi:10.1007/s00213-021-05876-x. PMID 34251464. S2CID 235796130.
  42. ^ a b Shulgin, Alexander T. (1991). Pihkal : a chemical love story. Ann Shulgin. Berkeley, CA: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
  43. ^ Riba, Jordi; Valle, Marta; Urbano, Gloria; Yritia, Mercedes; Morte, Adelaida; Barbanoj, Manel J. (July 2003). "Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics". Journal of Pharmacology and Experimental Therapeutics. 306 (1): 73–83. doi:10.1124/jpet.103.049882. ISSN 0022-3565. PMID 12660312. S2CID 6147566.
  44. ^ Haroz, Rachel; Greenberg, Michael I. (November 2005). "Emerging drugs of abuse". The Medical Clinics of North America. 89 (6): 1259–1276. doi:10.1016/j.mcna.2005.06.008. ISSN 0025-7125. PMID 16227062.
  45. ^ Strassman, Ruck J.; Qualls, Clifford R.; Uhlenhuth, Eberhard H.; Kellner, Robert (1994-02-01). "Dose-Response Study of N,N-Dimethyltryptamine in Humans: II. Subjective Effects and Preliminary Results of a New Rating Scale". Archives of General Psychiatry. 51 (2): 98–108. doi:10.1001/archpsyc.1994.03950020022002. ISSN 0003-990X. PMID 8297217.
  46. ^ Davis, Alan K; Clifton, John M; Weaver, Eric G; Hurwitz, Ethan S; Johnson, Matthew W; Griffiths, Roland R (September 2020). "Survey of entity encounter experiences occasioned by inhaled N,N -dimethyltryptamine: Phenomenology, interpretation, and enduring effects". Journal of Psychopharmacology. 34 (9): 1008–1020. doi:10.1177/0269881120916143. ISSN 0269-8811. PMID 32345112.
  47. ^ Creese, Ian; Burt, David R.; Snyder, Solomon H. (1975-12-01). "The dopamine receptor: Differential binding of d-LSD and related agents to agonist and antagonist states". Life Sciences. 17 (11): 1715–1719. doi:10.1016/0024-3205(75)90118-6. ISSN 0024-3205. PMID 1207384.
  48. ^ Passie, Torsten; Seifert, Juergen; Schneider, Udo; Emrich, Hinderk M. (October 2002). "The pharmacology of psilocybin". Addiction Biology. 7 (4): 357–364. doi:10.1080/1355621021000005937. PMID 14578010. S2CID 12656091.
  49. ^ Freye, E. (2009). Pharmacology and abuse of cocaine, amphetamines, ecstasy and related designer drugs : a comprehensive review on their mode of action, treatment of abuse and intoxication. Dordrecht: Springer. ISBN 978-90-481-2448-0. OCLC 489218895.
  50. ^ Griffiths, R. R.; Richards, W. A.; McCann, U.; Jesse, R. (August 2006). "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance". Psychopharmacology. 187 (3): 268–283. doi:10.1007/s00213-006-0457-5. ISSN 0033-3158. PMID 16826400. S2CID 7845214.
  51. ^ a b "4-HO-MiPT". Psychedelic Science Review. 2020-01-06. Retrieved 2022-07-06.
  52. ^ Carlini, E. A.; Maia, Lucas O. (2020). "Plant and Fungal Hallucinogens as Toxic and Therapeutic Agents". Plant Toxins. Toxinology. Springer Netherlands: 1–44. doi:10.1007/978-94-007-6728-7_6-2. ISBN 978-94-007-6728-7. S2CID 239438352. Retrieved 23 February 2022.
  53. ^ "History of Psychedelics: How the Mazatec Tribe Brought Entheogens to the World". Psychedelic Times. 28 October 2015. Retrieved 23 February 2022.
  54. ^ Ismael Eduardo Apud Peláez. (2020). Ayahuasca: Between Cognition and Culture. Publicacions Universitat Rovira i Virgili. ISBN 978-84-8424-834-7. OCLC 1229544084.
  55. ^ Bussmann RW, Sharon D (2006). "Traditional medicinal plant use in Northern Peru: tracking two thousand years of healing culture". J Ethnobiol Ethnomed. 2 (1): 47. doi:10.1186/1746-4269-2-47. PMC 1637095. PMID 17090303.
  56. ^ Socha, Dagmara M.; Sykutera, Marzena; Orefici, Giuseppe (2022-12-01). "Use of psychoactive and stimulant plants on the south coast of Peru from the Early Intermediate to Late Intermediate Period". Journal of Archaeological Science. 148: 105688. doi:10.1016/j.jas.2022.105688. ISSN 0305-4403. S2CID 252954052.
  57. ^ Larco, Laura (2008). "Archivo Arquidiocesano de Trujillo Sección Idolatrías. (Años 1768–1771)". Más allá de los encantos – Documentos sobre extirpación de idolatrías, Trujillo. Travaux de l'IFEA. Lima: IFEA Instituto Francés de Estudios Andinos, Fondo Editorial de la Universidad Nacional Mayor de San Marcos. pp. 67–87. ISBN 9782821844537. Retrieved April 9, 2020.
  58. ^ Anderson, Edward F. (2001). The Cactus Family. Pentland, Oregon: Timber Press. ISBN 978-0-88192-498-5. pp. 45–49.
  59. ^ "Declaran Patrimonio Cultural de la Nación a los conocimientos, saberes y usos del cactus San Pedro". (in Spanish). 2022-11-17. Retrieved 2022-12-10.
  60. ^ a b "Psychedelics Weren't As Common in Ancient Cultures As We Think". Vice Media. Vice. December 10, 2020. Retrieved January 14, 2023.
  61. ^ Pilecki, Brian; Luoma, Jason B.; Bathje, Geoff J.; Rhea, Joseph; Narloch, Vilmarie Fraguada (2021). "Ethical and legal issues in psychedelic harm reduction and integration therapy". Harm Reduction Journal. 18 (1): 40. doi:10.1186/s12954-021-00489-1. PMC 8028769. PMID 33827588.
  62. ^ Nutt, David; Erritzoe, David; Carhart-Harris, Robin (2020). "Psychedelic Psychiatry's Brave New World". Cell. 181 (1): 24–28. doi:10.1016/j.cell.2020.03.020. PMID 32243793. S2CID 214753833.
  63. ^ a b Johnson, M. W.; Richards, W. A.; Griffiths, R. R. (2008). "Human hallucinogen research: guidelines for safety". Journal of Psychopharmacology. 22 (6): 603–620. doi:10.1177/0269881108093587. PMC 3056407. PMID 18593734.
  64. ^ a b Garcia-Romeu, Albert; Richards, William A. (2018). "Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions". International Review of Psychiatry. 30 (4): 291–316. doi:10.1080/09540261.2018.1486289. ISSN 0954-0261. PMID 30422079. S2CID 53291327.
  65. ^ Romeo, Bruno; Karila, Laurent; Martelli, Catherine; Benyamina, Amine (2020). "Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis". Journal of Psychopharmacology. 34 (10): 1079–1085. doi:10.1177/0269881120919957. PMID 32448048. S2CID 218873949.
  66. ^ Schimmel, Nina; Breeksema, Joost J.; Smith-Apeldoorn, Sanne Y.; Veraart, Jolien; van den Brink, Wim; Schoevers, Robert A. (2022). "Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review". Psychopharmacology. 239 (15–33): 15–33. doi:10.1007/s00213-021-06027-y. PMID 34812901. S2CID 244490236.
  67. ^ "Breakthrough Therapy". United States Food and Drug Administration. 1 April 2018. Archived from the original on 1 March 2022. Retrieved 27 March 2022.
  68. ^ Krebs, Teri S.; Johansen, Pål-Ørjan (August 19, 2013). "Psychedelics and Mental Health: A Population Study". PLOS ONE. 8 (8): e63972. Bibcode:2013PLoSO...863972K. doi:10.1371/journal.pone.0063972. PMC 3747247. PMID 23976938.
  69. ^ Fadiman J (2016-01-01). "Microdose research: without approvals, control groups, double blinds, staff or funding". Psychedelic Press. XV.
  70. ^ Brodwin E (30 January 2017). "The truth about 'microdosing,' which involves taking tiny amounts of psychedelics like LSD". Business Insider. Retrieved 19 April 2017.
  71. ^ Dahl H (7 July 2015). "A Brief History of LSD in the Twenty-First Century". Psychedelic Press UK. Retrieved 19 April 2017.
  72. ^ Webb M, Copes H, Hendricks PS (August 2019). "Narrative identity, rationality, and microdosing classic psychedelics". The International Journal on Drug Policy. 70: 33–39. doi:10.1016/j.drugpo.2019.04.013. PMID 31071597. S2CID 149445841.
  73. ^ Chemistry, University of; Prague, Technology. "Recognizing signatures of psilocybin microdosing in natural language". Retrieved 2022-10-03.
  74. ^ Sanz, Camila; Cavanna, Federico; Muller, Stephanie; de la Fuente, Laura; Zamberlan, Federico; Palmucci, Matías; Janeckova, Lucie; Kuchar, Martin; Carrillo, Facundo; García, Adolfo M.; Pallavicini, Carla; Tagliazucchi, Enzo (2022-09-01). "Natural language signatures of psilocybin microdosing". Psychopharmacology. 239 (9): 2841–2852. doi:10.1007/s00213-022-06170-0. ISSN 1432-2072. PMID 35676541. S2CID 247067976.
  75. ^ "Crystal Structure of LSD and 5-HT2AR Part 2: Binding Details and Future Psychedelic Research Paths". Psychedelic Science Review. 2020-10-05. Retrieved 2021-02-12.
  76. ^ Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-McKenney KM, Gray JA, Olson DE (2018). "Psychedelics promote structural and functional neural plasticity". Cell Reports. 23 (11): 3170–3182. doi:10.1016/j.celrep.2018.05.022. PMC 6082376. PMID 29898390.
  77. ^ Vargas, Maxemiliano V.; Dunlap, Lee E.; Dong, Chunyang; Carter, Samuel J.; Tombari, Robert J.; Jami, Shekib A.; Cameron, Lindsay P.; Patel, Seona D.; Hennessey, Joseph J.; Saeger, Hannah N.; McCorvy, John D.; Gray, John A.; Tian, Lin; Olson, David E. (2023-02-17). "Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors". Science. 379 (6633): 700–706. doi:10.1126/science.adf0435. ISSN 0036-8075.
  78. ^ Wölfel, Reinhard; Graefe, Karl-Heinz (February 1992). "Evidence for various tryptamines and related compounds acting as substrates of the platelet 5-hydroxytryptamine transporter". Naunyn-Schmiedeberg's Archives of Pharmacology. 345 (2): 129–136. doi:10.1007/BF00165727. ISSN 0028-1298. PMID 1570019. S2CID 2984583.
  79. ^ Shimazu, Seiichiro; Miklya, Ildikó (May 2004). "Pharmacological studies with endogenous enhancer substances: β-phenylethylamine, tryptamine, and their synthetic derivatives". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 28 (3): 421–427. doi:10.1016/j.pnpbp.2003.11.016. PMID 15093948. S2CID 37564231.
  80. ^ Blough, Bruce E.; Landavazo, Antonio; Partilla, John S.; Baumann, Michael H.; Decker, Ann M.; Page, Kevin M.; Rothman, Richard B. (2014-06-12). "Hybrid Dopamine Uptake Blocker–Serotonin Releaser Ligands: A New Twist on Transporter-Focused Therapeutics". ACS Medicinal Chemistry Letters. 5 (6): 623–627. doi:10.1021/ml500113s. ISSN 1948-5875. PMC 4060932. PMID 24944732.
  81. ^ "4-HO-MET". The Drug Classroom. Retrieved 2022-07-31.
  82. ^ Shulgin, Alexander T. (Alexander Theodore) (1997). Tihkal : the continuation. Shulgin, Ann. (1st ed.). Berkeley, CA: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
  83. ^ Miller, Gregory M. (2010-12-16). "The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity". Journal of Neurochemistry. 116 (2): 164–176. doi:10.1111/j.1471-4159.2010.07109.x. ISSN 0022-3042. PMC 3005101. PMID 21073468.
  84. ^ Grandy, Gina (2020-04-23). "Guest editorial". Gender in Management. 35 (3): 257–260. doi:10.1108/GM-05-2020-238. ISSN 1754-2413.
  85. ^ Little, Karley Y.; Krolewski, David M.; Zhang, Lian; Cassin, Bader J. (January 2003). "Loss of Striatal Vesicular Monoamine Transporter Protein (VMAT2) in Human Cocaine Users". American Journal of Psychiatry. 160 (1): 47–55. doi:10.1176/appi.ajp.160.1.47. ISSN 0002-953X. PMID 12505801.
  86. ^ Brandt, Simon D.; Kavanagh, Pierce V.; Westphal, Folker; Stratford, Alexander; Odland, Anna U.; Klein, Adam K.; Dowling, Geraldine; Dempster, Nicola M.; Wallach, Jason; Passie, Torsten; Halberstadt, Adam L. (2020-04-20). "Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1‐cyclopropanoyl‐ d ‐lysergic acid diethylamide (1CP‐LSD)" (PDF). Drug Testing and Analysis. 12 (6): 812–826. doi:10.1002/dta.2789. ISSN 1942-7603. PMC 9191646. PMID 32180350. S2CID 212738912.
  87. ^ Grumann, Christina; Henkel, Kerstin; Brandt, Simon D.; Stratford, Alexander; Passie, Torsten; Auwärter, Volker (2020). "Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration". Drug Testing and Analysis. 12 (8): 1144–1153. doi:10.1002/dta.2821. ISSN 1942-7611. PMID 32415750.
  88. ^ Preller, Katrin H.; Vollenweider, Franz X. (2016). "Phenomenology, Structure, and Dynamic of Psychedelic States". In Adam L. Halberstadt; Franz X. Vollenweider; David E. Nichols (eds.). Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Vol. 36. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 221–256. doi:10.1007/7854_2016_459. ISBN 978-3-662-55878-2. PMID 28025814.
  89. ^ Swanson, Link R. (2018-03-02). "Unifying Theories of Psychedelic Drug Effects". Frontiers in Pharmacology. 9: 172. doi:10.3389/fphar.2018.00172. ISSN 1663-9812. PMC 5853825. PMID 29568270.
  90. ^ Luke, David (28 November 2013). "Rock Art or Rorschach: Is there More to Entoptics than Meets the Eye?". Time and Mind. 3 (1): 9–28. doi:10.2752/175169710x12549020810371. S2CID 144948636.
  91. ^ Berry, Mark D. (July 2004). "Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators". Journal of Neurochemistry. 90 (2): 257–271. doi:10.1111/j.1471-4159.2004.02501.x. ISSN 0022-3042. PMID 15228583. S2CID 12126296.
  92. ^ Luna, Luis Eduardo (1984). "The concept of plants as teachers among four mestizo shamans of Iquitos, northeastern Peru" (PDF). Journal of Ethnopharmacology. 11 (2): 135–156. doi:10.1016/0378-8741(84)90036-9. PMID 6492831. Retrieved 10 July 2020.
  93. ^ Nichols, David E. (April 2016). "Psychedelics". Pharmacological Reviews. 68 (2): 264–355. doi:10.1124/pr.115.011478.
  94. ^ "LSD: The Geek's Wonder Drug?". Wired. 16 January 2006. Retrieved 29 April 2008.
  95. ^ Majić T, Schmidt TT, Gallinat J (March 2015). "Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?". Journal of Psychopharmacology. 29 (3): 241–53. doi:10.1177/0269881114568040. PMID 25670401. S2CID 16483172.
  96. ^ Hanson, Dirk (29 April 2013). "When the Trip Never Ends". Dana Foundation.
  97. ^ Honig D. "Frequently Asked Questions". Erowid. Archived from the original on 12 February 2016.
  98. ^ McGlothlin W, Cohen S, McGlothlin MS (November 1967). "Long lasting effects of LSD on normals" (PDF). Archives of General Psychiatry. 17 (5): 521–32. doi:10.1001/archpsyc.1967.01730290009002. PMID 6054248. Archived from the original (PDF) on April 30, 2011.
  99. ^ Canadian government (1996). "Controlled Drugs and Substances Act". Justice Laws. Canadian Department of Justice. Archived from the original on December 15, 2013. Retrieved December 15, 2013.
  100. ^ Rogge T (May 21, 2014), Substance use – LSD, MedlinePlus, U.S. National Library of Medicine, archived from the original on July 28, 2016, retrieved July 14, 2016
  101. ^ CESAR (29 October 2013), LSD, Center for Substance Abuse Research, University of Maryland, archived from the original on July 15, 2016, retrieved 14 July 2016
  102. ^ Garcia-Romeu, Albert; Kersgaard, Brennan; Addy, Peter H. (August 2016). "Clinical applications of hallucinogens: A review". Experimental and Clinical Psychopharmacology. 24 (4): 229–268. doi:10.1037/pha0000084.
  103. ^ Byock, Ira (2018). "Taking Psychedelics Seriously". Journal of Palliative Medicine. 21 (4): 417–421. doi:10.1089/jpm.2017.0684. PMC 5867510. PMID 29356590.
  104. ^ a b van Amsterdam, Jan; Opperhuizen, Antoon; van den Brink, Wim (2011). "Harm potential of magic mushroom use: A review". Regulatory Toxicology and Pharmacology. 59 (3): 423–429. doi:10.1016/j.yrtph.2011.01.006. PMID 21256914.
  105. ^ Schlag, Anne K; Aday, Jacob; Salam, Iram; Neill, Jo C; Nutt, David J (2022-02-02). "Adverse effects of psychedelics: From anecdotes and misinformation to systematic science". Journal of Psychopharmacology. 36 (3): 258–272. doi:10.1177/02698811211069100. ISSN 0269-8811. PMC 8905125. PMID 35107059.
  106. ^ Krebs, Teri S.; Johansen, Pål-Ørjan; Lu, Lin (19 August 2013). "Psychedelics and Mental Health: A Population Study". PLOS ONE. 8 (8): e63972. Bibcode:2013PLoSO...863972K. doi:10.1371/journal.pone.0063972. PMC 3747247. PMID 23976938.
  107. ^ Baggott, M. J.; Coyle, J. R.; Erowid, E.; Erowid, F.; Robertson, L. C. (1 March 2011). "Abnormal visual experiences in individuals with histories of hallucinogen use: A web-based questionnaire". Drug and Alcohol Dependence. 114 (1): 61–67. doi:10.1016/j.drugalcdep.2010.09.006. PMID 21035275.
  108. ^ Bijl D (October 2004). "The serotonin syndrome". Neth J Med. 62 (9): 309–13. PMID 15635814. Mechanisms of serotonergic drugs implicated in serotonin syndrome... Stimulation of serotonin receptors... LSD
  109. ^ "AMT". 2016-01-03. Retrieved 2019-11-18.
  110. ^ Alpha‐methyltryptamine (AMT) – Critical Review Report (PDF) (Report). World Health Organisation – Expert Committee on Drug Dependence (published 2014-06-20). 20 June 2014. Retrieved 2019-11-18.
  111. ^ Boyer EW, Shannon M (March 2005). "The serotonin syndrome" (PDF). The New England Journal of Medicine. 352 (11): 1112–20. doi:10.1056/NEJMra041867. PMID 15784664. Archived (PDF) from the original on 2013-06-18.
  112. ^ Jones, K.A.; Srivastave, D.P.; Allen, J.A.; Roth, B.L.; Penzes, P. (2009). "Psychedelics Promote Structural and Functional Neural Plasticity". Proc Natl Acad Sci U S A. 106 (46): 19575–19580. doi:10.1073/pnas.0905884106. PMC 2780750. PMID 19889983.
  113. ^ Yoshida, H.; Kanamaru, C.; Ohtani, A.; Senzaki, K.; Shiga, T. (2011). "Subtype specific roles of serotonin receptors in the spine formation of cortical neurons in vitro". Neurosci Res. 71 (3): 311–314. doi:10.1016/j.neures.2011.07.1824. hdl:2241/114624. PMID 21802453. S2CID 14178672.
  114. ^ Ly, Calvin; Greb, Alexandra C.; Cameron, Lindsay P.; Wong, Jonathan M.; Barragan, Eden V.; Wilson, Paige C.; Burbach, Kyle F.; Soltanzadeh Zarandi, Sina; Sood, Alexander; Paddy, Michael R.; Duim, Whitney C.; Dennis, Megan Y.; McAllister, A. Kimberley; Ori-McKenney, Kassandra M.; Gray, John A.; Olson, David E. (June 2018). "Psychedelics Promote Structural and Functional Neural Plasticity". Cell Reports. 23 (11): 3170–3182. doi:10.1016/j.celrep.2018.05.022. PMC 6082376. PMID 29898390.
  115. ^ de Vos, Cato M. H.; Mason, Natasha L.; Kuypers, Kim P. C. (2021). "Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics". Frontiers in Psychiatry. 12: 1575. doi:10.3389/fpsyt.2021.724606. ISSN 1664-0640. PMC 8461007. PMID 34566723.
  116. ^ Calder, Abigail E.; Hasler, Gregor (2022-09-19). "Towards an understanding of psychedelic-induced neuroplasticity". Neuropsychopharmacology. 48 (1): 104–112. doi:10.1038/s41386-022-01389-z. ISSN 1740-634X. PMC 9700802. PMID 36123427. S2CID 252381170.
  117. ^ Nau, F.; Miller, J.; Saravia, J.; Ahlert, T.; Yu, B.; Happel, K.I; Cormier, S.A; Nichols, C.D. (2015). "Serotonin 5-HT₂ receptor activation prevents allergic asthma in a mouse model". American Journal of Physiology. Lung Cellular and Molecular Physiology. 308 (2): 191–198. doi:10.1152/ajplung.00138.2013. PMC 4338939. PMID 25416380.
  118. ^ Flanagan, T.W.; Sebastian, M.N.; Battaglia, D.M.; Foster, T.P.; Maillet, E.L.; Nichols, C.D. (2019). "Activation of 5-HT2 Receptors Reduces Inflammation in Vascular Tissue and Cholesterol Levels in High-Fat Diet-Fed Apolipoprotein E Knockout Mice". Sci. Rep. 9 (1): 13444–198. Bibcode:2019NatSR...913444F. doi:10.1038/s41598-019-49987-0. PMC 6748996. PMID 31530895.
  119. ^ Hicks, Michael (15 January 2000). Sixties Rock: Garage, Psychedelic, and Other Satisfactions. Chicago, IL: University of Illinois Press. pp. 63–64. ISBN 0-252-06915-3.
  120. ^ Krippner, Stanley (2017). "Ecstatic Landscapes: The Manifestation of Psychedelic Art". Journal of Humanistic Psychology. 57 (4): 415–435. doi:10.1177/0022167816671579. S2CID 151517152.
  121. ^ Dickins, Robert (2013). "Preparing the Gaia connection: An ecological exposition of psychedelic literature 1954-1963". European Journal of Ecopsychology. 4: 9–18. CiteSeerX Retrieved 7 January 2021.
  122. ^ Gallagher, Mark (2004). "Tripped Out: The Psychedelic Film and Masculinity". Quarterly Review of Film and Video. 21 (3): 161–171. doi:10.1080/10509200490437817. S2CID 191583864.
  123. ^ St John, Graham. "Neotrance and the Psychedelic Festival." Dancecult: Journal of Electronic Dance Music Culture, 1(1) (2009).
  124. ^ Hirschfelder, Adam (Jan 14, 2016). "The Trips Festival explained". Experiments in Environment: The Halprin Workshops, 1966–1971.
  125. ^ Rucker, James J. H. (2015). "Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential". British Medical Journal. 350: h2902. doi:10.1136/bmj.h2902. PMID 26014506. S2CID 46510541.
  126. ^ "U.S.C. Title 21 – FOOD AND DRUGS". Retrieved 28 February 2022.
  127. ^ "Pot Prohibition Continues Collapsing, and Psychedelic Bans Could Be Next". November 9, 2022.
  128. ^ "New Hampshire Lawmakers File Psilocybin And Broader Drug Decriminalization Bills For 2022". December 29, 2021.
  129. ^ Tuccille, J.D. (3 August 2022). "Scofflaws Lead the Way To Legalizing Psychedelic Drugs". Reason. Retrieved 18 January 2023.

Further reading